Incretin Mimetics Target Novel Pathways to Treat Type 2 Diabetes
About 194 million adults worldwide have diabetes, with over 174 million of these having type 2 diabetes. With a dramatic increase in disease prevalence expected, Lehman Brothers analysts predict the global diabetes market to reach $US21 billion by 2007. Other drivers include a shift in the treatment paradigm towards earlier insulinization, improved glucose control and the introduction of novel treatment options.
The scale of the diabetes problem presents several opportunities for pharmaceutical companies. While several therapies are available to treat diabetes, none actually address the underlying mechanisms of the disease. Incretin mimetics may fill this void. These agents mimic the effects of glucagon-like peptide-1 (GLP-1), a hormone that improves blood glucose. Drugs of this type include the GLP-1 analogs, of which Lilly/Amylin’s exenatide is the market leader and is awaiting US FDA registration, and the dipeptidyl peptidase IV (DPP IV) inhibitors, of which...
KeywordsMetformin Glycemic Control Liraglutide Exenatide Metformin Group
- 1.ADA 2004 preview. Lehman Brothers Global Equity Research (2004).Google Scholar